Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following their initial treatment.
Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following their initial treatment.